VC-backed Revance Therapeutics launches IPO

Revance Therapeutics debuted its IPO on Thursday after pricing its offering of 6 million shares at $16 per share. The stock is trading on the NASDAQ under the ticker symbol “RVNC.” Cowen and Company and Piper Jaffray are the underwriters. Based in Newark, California, Revance is a biopharmaceutical company that provides solutions for the way drugs are delivered. Its backers include Essex Woodlands Health Ventures, NovaQuest Capita, Technology Partners, Vivo Ventures, Shepherd Ventures, Palo Alto Investors, Pac-Link Ventures and Essex Capital Corp.


NEWARK, Calif., Feb. 5, 2014 (GLOBE NEWSWIRE) — Revance Therapeutics, Inc. (Revance), a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, announced today the pricing of its initial public offering of 6,000,000 shares of its common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions. The shares are expected to begin trading on The NASDAQ Global Market under the ticker symbol “RVNC” on February 6, 2014. In addition, Revance has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock at the same price to cover over-allotments, if any. The offering is expected to close on February 11, 2014, subject to customary closing conditions.
Cowen and Company and Piper Jaffray are acting as joint book-running managers for the offering. BMO Capital Markets is acting as lead manager. A registration statement relating to these securities was declared effective by the U.S. Securities and Exchange Commission on February 5, 2014. The offering is being made only by means of a written prospectus forming part of the effective registration statement. Copies of the prospectus relating to and describing the terms of the offering can be obtained by eligible investors from their Cowen and Company or Piper Jaffray sales representative, or from Cowen and Company, LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, Telephone: 631-274-2806, Fax: 631-254-7140; or from Piper Jaffray & Co., 800 Nicollet Mall, Suite 1000, Minneapolis, MN 55402, Telephone: (800) 747-3924, Email: [email protected]
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Revance Therapeutics
Revance Therapeutics, Inc. (Revance) is a specialty biopharmaceutical company which develops botulinum toxin products for use in aesthetic and therapeutic indications. Revance has developed a platform technology, TransMTS®, that enables local, targeted delivery of botulinum toxin and other potent macromolecules across skin without patches, needles or other invasive procedures.

Take your pick!

  • Buyouts delivers exclusive news and analysis about private equity deals, fundraising, top-quartile managers and more. Get your FREE trial or subscribe now.
  • VC Journal provides exclusive news and analysis about venture capital deals, fundraising, top-quartile investors and more. Get your FREE trial or subscribe now.